CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus
Fiche publication
Date publication
janvier 2016
Journal
European journal of radiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet, Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V
Lien Pubmed
Résumé
The first aim was to compare Response Evaluation Criteria in Solid Tumor (RECIST) 1.1, modified Response Evaluation Criteria in Solid Tumor (mRECIST), Choi and European Association for the Study of the Liver (EASL) evaluations to assess the response to sorafenib for hepatocellular carcinoma (HCC). The second aim was to describe the evolution of HCC and to identify whether some imaging features are predictive of the absence of response.
Mots clés
Adult, Aged, Antineoplastic Agents, therapeutic use, Carcinoma, Hepatocellular, diagnostic imaging, Female, Humans, Liver, diagnostic imaging, Liver Neoplasms, diagnostic imaging, Male, Middle Aged, Niacinamide, analogs & derivatives, Phenylurea Compounds, therapeutic use, Proportional Hazards Models, Response Evaluation Criteria in Solid Tumors, Retrospective Studies, Survival Analysis, Tomography, X-Ray Computed, Treatment Outcome
Référence
Eur J Radiol. 2016 Jan;85(1):103-12